Leonid Timashev
Stock Analyst at RBC Capital
(2.96)
# 1,523
Out of 4,479 analysts
34
Total ratings
42.31%
Success rate
1.33%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Reiterates: Outperform | $86 | $44.74 | +92.22% | 8 | Jun 21, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Reiterates: Outperform | $59 | $34.17 | +72.67% | 4 | Jun 18, 2024 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $31 | $20.30 | +52.71% | 3 | Jun 7, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $127 → $130 | $78.93 | +64.70% | 4 | Jun 5, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $28 → $32 | $18.38 | +74.10% | 5 | Apr 22, 2024 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $7 | $2.94 | +138.10% | 2 | Mar 22, 2024 | |
| DSGN Design Therapeutics | Reiterates: Sector Perform | $4 | $3.20 | +25.00% | 7 | Mar 20, 2024 | |
| NBSE NeuBase Therapeutics | Downgrades: Sector Perform | $240 → $20 | $0.38 | +5,191.01% | 1 | Oct 18, 2022 |
Legend Biotech
Jun 21, 2024
Reiterates: Outperform
Price Target: $86
Current: $44.74
Upside: +92.22%
Biohaven Pharmaceutical Holding Company
Jun 18, 2024
Reiterates: Outperform
Price Target: $59
Current: $34.17
Upside: +72.67%
NewAmsterdam Pharma Company
Jun 7, 2024
Reiterates: Outperform
Price Target: $31
Current: $20.30
Upside: +52.71%
Axsome Therapeutics
Jun 5, 2024
Maintains: Outperform
Price Target: $127 → $130
Current: $78.93
Upside: +64.70%
Edgewise Therapeutics
Apr 22, 2024
Maintains: Outperform
Price Target: $28 → $32
Current: $18.38
Upside: +74.10%
Pyxis Oncology
Mar 22, 2024
Reiterates: Outperform
Price Target: $7
Current: $2.94
Upside: +138.10%
Design Therapeutics
Mar 20, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $3.20
Upside: +25.00%
NeuBase Therapeutics
Oct 18, 2022
Downgrades: Sector Perform
Price Target: $240 → $20
Current: $0.38
Upside: +5,191.01%